YOLFTbeta
IRLAB Therapeutics AB (publ)

IRLAB Therapeutics AB (publ)

IRLAB-A · ST · Healthcare / Biotechnology

0.848SEK+0.23 (+36.77%)

Price History

Full chart

Market Stats

Previous Close0.62
Open0.74
Day Range0.70 – 0.915
52-Week Range1.17 – 2.93
Volume44.25M
Market Cap276.01M
P/E (TTM)0.00
Forward P/E23.36
EPS-0.44
Dividend Yield0.00%
Beta0.56
50-Day Avg1.66
200-Day Avg1.56

About

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of falling and falls in Parkinson's disease, and in a Phase IIA clinical trial for dementia in Parkinson's disease; and IRL757, which is in a Phase I clinical trial for the treatment of apathy in Parkinson's and other neurological disorders. It is also developing products in the preclinical stage, such as IRL942, an oral tablet for the treatment of cognitive deficits in Parkinson's and other neurological disorders; and IRL1117, an oral treatment for the hallmark symptoms of Parkinson's. In addition, the company develops P003, a research project that discovers and develops dopamine D1 and D2 receptor agonist compounds for the treatment of Parkinson's core motor symptoms. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Kristina Torfgard Ph.D.
  • Employees31
  • HeadquartersArvid Wallgrens Backe 20, Gothenburg, Sweden, 413 46, Sweden
  • Websitehttps://irlab.se

Leadership

  • Dr. Kristina Torfgard Ph.D.Chief Executive Officer · b. 1963
  • Mr. Gustaf Albèrt M.Sc.Chief Financial Officer · b. 1968
  • Dr. Peder Svensson Ph.D.Chief Information Officer and Director of Computational Chemistry & Biology · b. 1962
  • Ms. Cecilia Tivert Stenberg B.Sc.Head of Finance & Human Resource and Director of Accounting & Human Resources · b. 1957
  • Dr. Nicholas Waters Ph.D.Executive VP and Head of R&D · b. 1962
  • Dr. Joakim Tedroff M.D., Ph.D.Chief Medical Officer · b. 1961

Financials

Income Statement

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue54.00K2.88M144.00K109.00K18.00K26.00K300.00K207.78M61.14M5.68M94.63M57.46M
Growth (%)-+5233.33%-95.00%-24.31%-83.49%+44.44%+1053.85%+69160.67%-70.58%-90.71%+1566.57%-39.28%
Cost of Revenue13.95M30.67M49.16M10.13M74.09M96.23M2.00M39.09M172.37M128.41M187.05M149.81M
Gross Profit-13.90M-27.79M-49.02M-10.02M-74.08M-96.20M-1.70M168.69M-111.23M-122.73M-92.42M-92.35M
Gross Margin-25738.89%-964.90%-34042.36%-9191.74%-411527.78%-370011.54%-565.67%81.19%-181.94%-2161.57%-97.67%-160.71%
Operating Expense577.00K-218.00K178.00K44.20M-178.00K-355.00K89.76M116.11M1.88M58.03M-17.31M0
Operating Income-14.48M-27.57M-49.20M-54.22M-73.90M-95.85M-91.46M52.58M-113.11M-180.76M-75.11M-92.35M
Operating Margin-26807.41%-957.33%-34165.97%-49742.20%-410538.89%-368646.15%-30486.00%25.30%-185.01%-3183.60%-79.38%-160.71%
EBITDA-14.11M-27.31M-45.73M-53.87M-72.56M-93.17M-89.46M55.79M-109.13M-173.32M-68.07M-88.03M
EBITDA Margin-26131.48%-948.23%-31760.42%-49422.02%-403138.89%-358365.38%-29820.00%26.85%-178.50%-3052.55%-71.93%-153.20%
Net Income3.12M-11.89M-42.70M-56.23M-74.10M-96.32M-91.85M51.78M-114.20M-177.84M-83.13M-110.01M
Net Income Margin5781.48%-412.74%-29650.00%-51582.57%-411661.11%-370453.85%-30616.00%24.92%-186.80%-3132.07%-87.85%-191.45%
R&D15.52M26.23M38.96M45.22M58.93M79.38M76.25M39.35M146.18M151.31M163.67M130.79M
R&D as % of Total Revenue28744.44%910.66%27058.33%41485.32%327372.22%305311.54%25416.00%18.94%239.10%2664.88%172.96%227.60%
Interest Expense86.00K137.00K24.00K2.01M202.00K272.00K195.00K370.00K297.00K199.00K10.48M17.99M
Interest Expense % of Total Revenue159.26%4.76%16.67%1840.37%1122.22%1046.15%65.00%0.18%0.49%3.50%11.07%31.30%

Balance Sheet

Currency: SEK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets25.00M106.43M101.09M113.11M162.97M224.94M208.07M370.07M472.45M323.56M177.12M136.21M138.21M
Total Liabilities7.00K17.86M9.06M9.22M7.97M12.46M26.24M22.19M72.97M32.72M61.36M103.58M107.49M
Total Equity24.99M50.57M92.03M103.89M155.00M212.48M181.83M347.88M399.48M290.83M115.76M32.63M30.72M
Cash-19.67M14.42M25.74M74.71M134.44M110.53M277.01M401.90M252.78M111.31M66.92M81.86M
Total Debt--400.00K400.00K--4.54M2.93M6.60M3.98M27.57M60.42M29.95M
Net Debt--19.67M-14.02M-25.34M-74.71M-134.44M-105.98M-274.08M-395.30M-248.80M-83.74M-6.50M-51.91M

Cash Flow

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.02M-27.66M-40.82M-57.74M-70.79M-91.20M-89.21M128.64M-142.61M-164.85M-65.59M-55.22M
Investing Cash Flow9.69M--219.00K-222.00K-1.05M-137.00K-394.00K-708.00K-3.38M-293.00K-199.00K0
Financing Cash Flow21.00M22.41M52.35M106.94M131.57M67.42M256.09M-3.04M-3.13M23.68M21.40M73.41M
Capital Expenditure00219.00K222.00K1.05M137.00K394.00K708.00K3.38M293.00K199.00K0
Free Cash Flow-11.02M-27.66M-41.04M-57.96M-71.84M-91.34M-89.61M127.93M-145.99M-165.14M-65.79M-55.22M
Dividends Paid-------3.23M----
FCF to OCF100.00%100.00%100.54%100.38%101.49%100.15%100.44%99.45%102.37%100.18%100.30%100.00%
Dividend Paid to FCF-------2.52%----

Earnings

Report DateMay 16, 2017Aug 29, 2017Nov 15, 2017Feb 27, 2018May 16, 2018Aug 29, 2018Nov 14, 2018Feb 27, 2019Apr 25, 2019Aug 28, 2019Nov 7, 2019Feb 6, 2020May 7, 2020Aug 26, 2020Nov 11, 2020Feb 24, 2021May 6, 2021Aug 25, 2021Nov 10, 2021Feb 23, 2022May 11, 2022Aug 24, 2022Nov 9, 2022Feb 23, 2023May 10, 2023Aug 30, 2023Oct 25, 2023Feb 7, 2024May 8, 2024Jul 10, 2024Oct 30, 2024Feb 12, 2025May 6, 2025Aug 27, 2025Oct 29, 2025Feb 25, 2026May 6, 2026Aug 26, 2026Nov 13, 2026
EPS Estimate---------------------0.65-0.90-1.09----------------
EPS Actual-0.39-0.30-0.58-0.36-0.45-0.63-0.38-0.45-0.43-0.74-0.52-0.63-0.42-0.54-0.56-0.40-0.39-0.512.35-0.45-0.56-0.52-0.46-0.64-1.15-0.87-0.74-0.67-0.75-0.14-0.61-0.10-0.65-0.62-0.24-0.290.11-0.23-
Surprise--------------------13.85%42.22%57.80%----------------
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap276.01M
Enterprise Value256.47M
Trailing P/E0.00
Forward P/E23.36
Price / Sales3.48
Price / Book2.74
EPS-0.44
Book Value0.653
Revenue (TTM)79.33M
Gross Profit (TTM)787.00K
EBITDA-37.95M
Profit Margin-67.87%
Operating Margin-260.85%
Return on Equity-155.06%
Return on Assets-16.16%
Shares Outstanding148.63M
Shares Float119.85M
Beta0.56
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 28, 20195:1